Long-Term Effects of Peptide Use: What the Data Show

Why long-term data are scarce

In drug research, "long-term" usually means a year or more of controlled follow-up. Few peptides have that, and the ones that do are prescription medicines, because regulators want long safety studies before approval. Most peptides sold online as "research use only" never got that far. Some stalled in early trials; others were only tested in rodents.

So the answer to "what does years of peptide use do?" depends on the peptide. For most compounds lifters buy, the longest human data cover weeks, and sometimes there are none. This page sorts what exists by compound and notes where community belief has run ahead of the studies. Short-term side effects and gray-market quality problems are covered in our overview of the health risks of peptide use.

Longest human data by compound

Approved peptide drugs: real long-term data

Semaglutide has the deepest record of any peptide. The SELECT trial gave 17,604 adults with heart disease and overweight (but no diabetes) 2.4 mg weekly or placebo, with an average follow-up of 39.8 months. Major cardiovascular events occurred in 6.5% on semaglutide versus 8.0% on placebo. Tolerability was the cost: 16.6% stopped the drug because of adverse events, about twice the placebo rate.

Stopping matters too. In the STEP 1 extension, people who had lost 17.3% of their weight over 68 weeks regained about two-thirds of that loss within a year off the drug. The Wegovy label carries a boxed warning because semaglutide causes thyroid C-cell tumors in rodents; the human relevance "has not been determined." Our page on fat-loss peptides compares semaglutide with newer drugs.

Tesamorelin is the one approved drug that acts on the same growth hormone pathway as the research secretagogues, so its label is a useful guide. Its trials in HIV-associated abdominal fat ran 26 weeks plus a 26-week extension at 2 mg daily. At 26 weeks, 47% of patients had IGF-1 more than 2 standard deviations above normal, and HbA1c reached 6.5% or higher in 5% versus 1% on placebo. The label says plainly: "The effects of prolonged elevations in IGF-1 levels are unknown." It calls for monitoring IGF-1 and glucose and rules out use in active cancer. See our tesamorelin clinical overview for the trials.

Growth hormone secretagogues: what the studies show

GHRH analogs such as sermorelin and CJC-1295 amplify the brain's own release signal to the pituitary. Ghrelin receptor agonists such as ipamorelin and hexarelin add a separate signal, as does the oral compound MK-677. Both families reliably raise GH and IGF-1 in people. Data on years of use are much thinner.

Desensitization. The longest direct test is small. Twelve healthy older adults injected hexarelin twice daily for 16 weeks, and their GH response fell by about 45%. Four weeks after stopping, it was back to baseline: the loss was partial and it reversed. GH and IGF-1 stayed raised through the 2-year MK-677 trial.

The CJC-1295 "GH bleed" claim. Community guides often say CJC-1295 with DAC (half-life roughly 6-8 days) flattens natural GH pulses into a constant low-level "bleed." The one human study that measured this found otherwise. Healthy men aged 20-40 got a single 60 or 90 mcg/kg injection, with overnight GH sampled every 20 minutes before and one week after. Pulse frequency and size were unchanged. Trough GH rose about 7.5-fold, which lifted mean GH by 46%. The extra GH sat underneath intact pulses instead of replacing them.

That was one dose, checked once. Nobody has published pulse data after months of repeated dosing, which is how users take it. The longest human exposure on record is a Phase 2 trial in HIV lipodystrophy. According to FDA's 2024 advisory committee review, it was stopped when a participant had a fatal heart attack two hours after the 11th weekly dose; the attending physician blamed undiagnosed coronary disease, and the data were never published.

Ipamorelin's "clean" reputation. Ipamorelin is often called the cleanest secretagogue because of a 1998 swine study in which GHRP-2 and GHRP-6 raised cortisol and ipamorelin didn't. Our evidence rating for it is moderate. Human data come down to one IV dosing study in healthy men and one Phase 2 trial in adults recovering from bowel surgery, who got IV ipamorelin twice daily for up to a week. That trial missed its main goal. FDA's 2024 review noted more hypokalemia (low potassium) and hyperglycemia in the ipamorelin group, along with more insomnia. Two patients in that group died after treatment ended; causality wasn't established. Nothing is known about use beyond that week.

Heart, fluid and blood sugar

The main reason for caution about raising GH for years comes from acromegaly, a disease of chronic GH excess. A 2018 review calls acromegalic cardiomyopathy the leading cause of illness and death in these patients. Acromegaly often means years of untreated GH excess from a pituitary tumor, so it shows the direction of risk, not its size for someone using a secretagogue.

Shorter-term signals point the same way. The tesamorelin label lists swelling and joint pain, plus carpal tunnel syndrome, as GH-related effects that fade or resolve after stopping. Blood sugar is the most consistent finding. Over two years, MK-677 at 25 mg a day raised fasting glucose about 5 mg/dL and lowered insulin sensitivity; cortisol rose too. Tesamorelin raised HbA1c, and the ipamorelin trial saw more hyperglycemia. FDA also lists MK-677 as a compounding safety risk after a hip-fracture trial in older adults stopped early over a heart failure signal. Whether these changes add up to diabetes or heart disease over years of unsupervised use hasn't been studied.

Repair peptides and other research compounds

For BPC-157 and TB-500, there are no long-term human data. A 2025 systematic review of BPC-157 found 36 studies, 35 of them preclinical; animal safety studies stopped at six weeks, and there were no clinical safety data. We rate BPC-157's evidence as emerging. For the TB-500 fragment, rated preliminary, FDA says it has found no human exposure data at all.

Users often call these peptides low-risk because they don't act on the GH axis. That does remove the concerns above, but "no known long-term risk" here means nobody has looked. The same review describes BPC-157 switching on cell-growth pathways and angiogenesis in animal and cell studies; its long-term effect in either direction is untested. Gray-market quality adds its own exposure, since every dose from a bad vial repeats the risk.

What users report

Cycling is the usual community answer to long-term use of GH secretagogues. Community guides commonly describe about 8-12 weeks on and 4-8 weeks off, on the theory that a break restores pituitary response. The hexarelin data fit the idea that the response recovers within weeks, but no trial has compared schedules or shown that cycling prevents harm. Many users also get IGF-1 checked before and during a course, often with fasting glucose or HbA1c, which mirrors the tesamorelin label. Our guide to monitoring and contraindications covers the tests.

What we still don't know

• Whether CJC-1295 with DAC leaves GH pulses intact after months of repeated doses.
• Whether IGF-1 kept at or above the top of the normal range for years raises cancer or heart risk in healthy adults.
• Whether BPC-157 or TB-500 will ever get long-term safety data. In July 2026, FDA's compounding advisers voted 8-6 to recommend both for the 503A bulks list, against FDA staff advice. As of October 2026, no proposed rule has been published, and that review doesn't require clinical trials.
• What the LUM-201 (MK-677) Phase 3 shows. It began recruiting about 150 children with GH deficiency in May 2026, with primary completion expected in December 2027.